BCI
DNTH icon

Brinker Capital Investments’s Dianthus Therapeutics DNTH Stock Holding History

Brinker Capital Investments’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$352K Sell
3,610
-678
-16% -$59.2K ﹤0.01% 1580
2026
Q1 		$360K Buy
+4,288
New +$248K ﹤0.01% 1587

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Brinker Capital Investments's DNTH Position: Q2 2026 in Review

Brinker Capital Investments reduced its Dianthus Therapeutics (DNTH) stake by 16% in Q2 2026, selling an estimated $59.2K and leaving 3,610 shares worth $352K. The position accounts for ﹤0.01% of the portfolio, ranked #1580.

Brinker Capital Investments first reported a position in DNTH in Q1 2026 and has held it in 2 quarters since. The position peaked at $360K in Q1 2026. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Brinker Capital Investments held 3,610 shares of Dianthus Therapeutics worth $352K as of Q2 2026.
  • Brinker Capital Investments sold 678 Dianthus Therapeutics shares in Q2 2026, an estimated $59.2K.
  • Dianthus Therapeutics made up ﹤0.01% of Brinker Capital Investments's portfolio in Q2 2026, its #1580 holding.
  • Brinker Capital Investments first reported a position in Dianthus Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Brinker Capital Investments's Dianthus Therapeutics position peaked at $360K in Q1 2026.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.